Article Information
History
- May 17, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Danmei Su1,*,
- Xinglin Li1,
- Cui He1,
- Xueqing Huang1,
- Meilin Chen1,
- Qiang Wang1,
- Wenchang Qin1,
- Ying Liang1,
- Rong Xu1,
- Jinhua Wu1,
- Peiwen Luo1,
- Xiaofang Yang1,
- Yilan Zeng2,
- Mei Luo2,
- Dongxia Luo2,
- David M Salisbury3,
- Donna Ambrosino3,
- George Siber3,
- Ralf Clemens3,
- Peng Liang1 and
- Joshua G. Liang1,*,†
- 1Clover Biopharmaceuticals, Chengdu, China
- 2Public Health Clinical Center of Chengdu, Chengdu, China
- 3Scientific Advisory Board, Clover Biopharmaceuticals, Chengdu, China
- ↵†Corresponding author. Email: joshua.liang{at}cloverbiopharma.com
↵* These authors contributed equally to this work
Posted May 17, 2021.
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate
